RESUMO
Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.
RESUMO
In a population-based study survival after recurrence was compared in three cohorts of patients with a primary diagnosis of breast cancer in 1959, 1969 and 1979, respectively. The use of chemotherapy after recurrence in these cohorts was either none, sporadic or widespread. This allowed a retrospective analysis of the survival impact of chemotherapy. Given the basic assumption that the natural history of breast cancer and the influence of endocrine therapy have not changed significantly during the 20-year period covered by the study, our data suggest that chemotherapy in recurrent breast cancer prolongs survival by 9.5 months in patients who survive more than 2 weeks from the start of treatment for this recurrence.
Assuntos
Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/mortalidade , Recidiva Local de Neoplasia/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/patologia , Estudos de Coortes , Feminino , Humanos , Pessoa de Meia-Idade , Análise de Sobrevida , Fatores de TempoRESUMO
Tauromustine was administered orally in weekly doses with interindividual dose escalation to patients with disseminated malignant melanoma. The dose in the first cohort of 6 patients was 20 mg/m2/week. The dose escalation was 5 mg/m2/week. The limit of tolerance was 55 mg/m2/week. 99 patients completed at least 8 weeks of treatment and eight dose levels were evaluated for toxicity. Reversible thrombocytopenia, and to a lesser degree leukopenia, were dose limiting. From a starting dose of 40 mg/m2/week, the long-term tolerated dose was 35 mg/m2/week, thus achieving a considerable increase of dose intensity without a significant increase of toxicity by employing this weekly schedule of tauromustine.
Assuntos
Antineoplásicos/uso terapêutico , Melanoma/tratamento farmacológico , Compostos de Nitrosoureia/administração & dosagem , Taurina/análogos & derivados , Administração Oral , Adulto , Idoso , Esquema de Medicação , Feminino , Humanos , Leucopenia/induzido quimicamente , Masculino , Pessoa de Meia-Idade , Compostos de Nitrosoureia/efeitos adversos , Taurina/administração & dosagem , Taurina/efeitos adversos , Trombocitopenia/induzido quimicamenteRESUMO
In a population-based study survival after recurrence was compared in three cohorts of patients each with a primary diagnosis of breast cancer in either 1959, 1969 end 1979. The use of chemotherapy after recurrence in these cohorts was either none, sporadic or widespread. This allowed a retrospective analysis of the survival impact of chemotherapy. Our data suggest that chemotherapy in recurrent breast cancer prolongs survival by 9.5 months in patients who survive more than two weeks from the start of treatment for their recurrence, given the basic assumption that the natural history of breast cancer and the influence of endocrine therapy have not changed significantly during the 20-year period covered by the study.